Acalabrutinib in Chinese Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): 12-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial

被引：0

作者：

Yang, Shenmiao ^{[1
]}

Huang, Haiwen ^{[2
]}

Zhou, Keshu ^{[3
]}

Zhao, Xielan ^{[4
]}

Han, Yanqiu ^{[5
]}

Li, Lindong ^{[6
]}

Butturini, Anna ^{[7
]}

Wang, Yujie ^{[6
]}

Liu, Xiaofeng ^{[6
]}

Lai, Peiqiong ^{[6
]}

Li, Jianyong ^{[8
]}

机构：

[1] Peking Univ Peoples Hosp, Peking Univ Inst Hematol, Beijing, Peoples R China

[2] Soochow Univ, Suzhou Hongci Hematol Hosp, Affiliated Hosp 1,Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol,Dept Hematol, Suzhou, Peoples R China

[3] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Canc Hosp, Zhengzhou, Peoples R China

[4] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China

[5] Inner Mongolia Med Univ, Affiliated Hosp, Hohhot, Peoples R China

[6] AstraZeneca, Shanghai, Peoples R China

[7] AstraZeneca, San Francisco, CA USA

[8] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173399

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3